Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162253 · ClinicalTrials.gov registry record · Phase 2
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00162253 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 120 participants.
The verdict
NCT00162253, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
Interventions
- DRUG BMS 587101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162253
The ClinicalTrials.gov registry entry for NCT00162253 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS 587101 is the first listed.
NCT00162253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162253 about?
NCT00162253 is a clinical study titled "Study of BMS-587101 in Patients With Moderate to Severe Psoriasis". The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
What is the current status of trial NCT00162253?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00162253?
The interventions under investigation include: BMS 587101 (DRUG).
Who is sponsoring clinical trial NCT00162253?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.